NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This prospective, multicenter, non-interventional study (NIS) in Germany aims to collect real-life data of patients with non-squamous (NSQ) metastatic non-small cell lung cancer (mNSCLC) (incl. large cell neuroendocrine carcinoma (LCNEC) if considered NSCLC-like by the treating physician) for whom 1st line treatment initiation with tremelimumab and durvalumab in combination with a platinum-based chemotherapy (TDC) according to marketing authorization was scheduled. The study aims to describe the effectiveness with respect to mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS), Serine/threonine kinase 11 (STK11), Kelch-like ECH-associated protein 1 (KEAP1), and Tumor protein p53 (TP53) as well as expression of Thyroid transcription factor 1 (TTF-1) and Programmed death-ligand 1 (PD-L1) in routine clinical practice. The generated data aims to deepen the understanding of optimal, biomarker-guided treatment strategies for NSQ mNSCLC in distinct subgroups with a high medical need.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek powyżej 18 lat
- •Decyzja rozpoczęcia pierwszej linii leczenia kombinacją trzech leków (tremelimumab, durvalumab i chemioterapia platynowa)
- •Potwierdzony rak płuca bez komórek płaskich z przerzutami
- •Brak określonych mutacji genetycznych (EGFR lub ALK)
- •Przeprowadzone badania genetyczne (NGS) obejmujące geny: KRAS, STK11, KEAP1 i TP53
- •Przeprowadzona analiza białka TTF-1
- •Przeprowadzona analiza białka PD-L1
- •Kobiety w wieku rozrodczym muszą stosować antykoncepcję podczas i przez 3 miesiące po leczeniu
✗ Disqualifies
- •Uczestnictwo w innym badaniu klinicznym
- •Przeciwwskazania medyczne do stosowania tych leków
- •Inne nowotwory oprócz raka płuca z przerzutami
- •Rak płuca z mieszaną strukturą (komórki płaskie i bezpłatkowe)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 120 Years
- Last updated (source)
- August 20, 2026
- Sex
- No restrictions
Locations (30)
Research Site
Bad Homburg, Germany
Research Site
Berlin, Germany
Research Site
Bremen, Germany
Research Site
Celle, Germany
Research Site
Chemnitz, Germany
Research Site
Cologne, Germany
Research Site
Deggendorf, Germany
Research Site
Frankfurt, Germany
Research Site
Georgsmarienhütte, Germany
Research Site
Gera, Germany
Research Site
Goslar, Germany
Research Site
Greifswald, Germany
Research Site
Halle-Dolau, Germany
Research Site
Hanover, Germany
Research Site
Herne, Germany
Research Site
Hösbach, Germany
Research Site
Koblenz, Germany
Research Site
Koln-Mehrheim, Germany
Research Site
Mainz, Germany
Research Site
Marburg, Germany
Research Site
Münnerstadt, Germany
Research Site
Neuss, Germany
Research Site
Offenbach, Germany
Research Site
Querfurt, Germany
Research Site
Ravensburg, Germany
Research Site
Rüsselsheim am Main, Germany
Research Site
Treuenbrietzen, Germany
Research Site
Ulm, Germany
Research Site
Wiesbaden, Germany
Research Site
Zwickau, Germany
Trial contact
AstraZeneca Clinical Study Information Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.